0000899243-20-025166.txt : 20200915
0000899243-20-025166.hdr.sgml : 20200915
20200915201040
ACCESSION NUMBER: 0000899243-20-025166
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200911
FILED AS OF DATE: 20200915
DATE AS OF CHANGE: 20200915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Katkin Keith
CENTRAL INDEX KEY: 0001314596
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36620
FILM NUMBER: 201177125
MAIL ADDRESS:
STREET 1: C/O UROVANT SCIENCES, INC.
STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Novus Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
BUSINESS PHONE: 949-238-8090
MAIL ADDRESS:
STREET 1: 19900 MACARTHUR BLVD.
STREET 2: SUITE 550
CITY: IRVINE
STATE: CA
ZIP: 92612
FORMER COMPANY:
FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070622
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-11
0
0001404281
Novus Therapeutics, Inc.
NVUS
0001314596
Katkin Keith
C/O NOVUS THERAPEUTICS, INC.
19900 MACARTHUR BLVD., SUITE 550
IRVINE
CA
92612
1
0
0
0
Stock Option (Right to Buy)
500.00
2020-09-11
4
A
0
5907.15
0.00
A
2030-09-11
Series X1 Convertible Preferred Stock
5907.15
5907.15
D
This option represents a right to purchase a total of 5,907.15 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c).
Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.
/s/ Ryan A. Murr, as attorney-in-fact for Keith Katkin
2020-09-15